Articles by PrECOG Cancer Research Group

New First-Line Lymphoma Treatment Well-Tolerated in Phase 2 Trial

Venetoclax administered with bendamustine+rituximab as the first therapy for mantle cell lymphoma led to 85 percent complete response rate